Peregrine Pharmaceuticals - Articles and news items

Bavituximab and durvalumab combo to be evaluated in solid tumours

Industry news / 24 August 2015 / Victoria White

AstraZeneca and Peregrine Pharmaceuticals are to evaluate the safety and efficacy of Peregrine’s bavituximab in combination with AstraZeneca’s durvalumab…

 

The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...
+